Related by context. All words. (Click for frequent words.) 69 median PFS 68 melphalan prednisone 68 progression TTP 67 VELCADE melphalan 66 disease progression TTP 65 Kaplan Meier analysis 65 6 mercaptopurine 65 Median PFS 65 % CI #.#-#.# [003] 64 Free Survival PFS 64 FOLFIRI alone 64 plus prednisone 64 CR nPR 64 FOLFIRI 64 % CI #.#-#.# [007] 64 free survival PFS 63 #mg BID [003] 63 postintervention 63 pCR 63 achieved ACR# 63 biochemical recurrence 63 FOLFOX4 63 median survivals 62 placebo dexamethasone 62 definite stent thrombosis 62 lymphocytosis 62 neurologic progression 62 postoperative chemotherapy 62 biochemical relapse 62 locoregional recurrence 62 HBeAg seroconversion 61 primary patency 61 lopinavir r 61 binary restenosis 61 univariate analysis 61 pegylated interferon alfa 2b 61 squamous histology 61 P = .# 61 relapsed MM 61 recurrent GBM 61 reinfarction 61 PIP joints 61 HbA 1c levels 61 prospectively defined 61 tumor progression TTP 61 tipranavir r 61 8mg/kg 61 severe exacerbations 61 doxorubicin docetaxel 60 pT2 60 5-FU/LV 60 LV dysfunction 60 locoregional 60 mg kg dose 60 DES implantation 60 paclitaxel carboplatin 60 KRAS mutant tumors 60 SVR# 60 rimonabant #mg 60 neoadjuvant 60 TEAEs 60 clodronate 60 stage IIIb IV 60 remission CR 60 paclitaxel eluting stents 60 microbiologically evaluable 60 mitoxantrone plus 60 recurrent VTE 60 chlorambucil 60 PSA nadir 60 pegylated liposomal doxorubicin 60 angiographic restenosis 60 mg ustekinumab 60 FOLPI 60 Operative mortality 59 achieved CCyR 59 APTIVUS r 59 periprocedural 59 virologic response 59 chemoradiation 59 LVEF 59 Secondary endpoints 59 dose dexamethasone 59 carboplatin paclitaxel 59 oblimersen 59 oxycodone CR 59 estramustine 59 EGFR mutation positive 59 heavily pretreated patients 59 adjuvant cisplatin 59 Doxil ® 59 gemcitabine carboplatin 59 CR CRu 59 CCyR 59 CLL SLL 59 complete cytogenetic response 59 plus gemcitabine 59 PASI scores 59 resected pancreatic cancer 59 mRCC 59 HbA1C levels 59 low dose Iluvien 59 azathioprine 59 undetectable HBV DNA 59 Stent thrombosis 59 antiretroviral naïve 59 chemoradiotherapy 59 pT3 59 thromboembolic events 59 NATRECOR R 59 mitoxantrone 59 perioperative complications 59 diameter stenosis 59 vinorelbine 59 #mg/m# [001] 59 symptomatic VTE 59 Median progression 59 systemic embolism 59 underwent surgical resection 59 severe neutropenia 58 lumbar spine BMD 58 endoscopic remission 58 Partial Response 58 MADRS score 58 perioperative mortality 58 everolimus eluting stents 58 leucopenia 58 plus OBT 58 PSADT 58 Subgroup analysis 58 5-fluorouracil/leucovorin 58 dalteparin 58 docetaxel pretreated 58 metastatic renal cell carcinoma 58 oral Hycamtin 58 FOLFOX4 alone 58 receiving VICTRELIS 58 QTc prolongation 58 preoperative chemotherapy 58 angiographic outcomes 58 ipsilateral stroke 58 de novo AML 58 arterial thromboembolic events 58 Thal Dex 58 evaluable 58 plus dexamethasone 58 Secondary endpoints included 58 FOLFOX 58 abacavir lamivudine 58 certolizumab 58 MACCE 58 elevated LDH 58 recurrent ischemia 58 XIENCE V PROMUS Stent 58 5FU 58 TURBT 58 multivariable analysis 58 mycophenolate mofetil 58 postoperative complication 58 visceral metastases 58 Folfox 58 ug dose 58 neutrophil counts 58 NMIBC 58 mcg QD 58 doxorubicin cyclophosphamide 58 p = NS 58 intravitreal injections 58 patients evaluable 58 underwent resection 58 debulking surgery 58 chemoradiation therapy 58 nadolol 58 Events MACE 58 elevated ALT 58 Adjuvant chemotherapy 58 EDSS scores 58 IFN alfa 58 evaluable patients 58 tipranavir ritonavir 58 recurrent NSCLC 58 BEACOPP 58 GLIADEL R Wafer 58 QTcF 58 invasive carcinomas 58 comparator arm 58 octreotide LAR 58 adjuvant tamoxifen 58 response pCR 58 mg/m2 dose 58 evaluable subjects 58 pretreatment baseline 58 CLARITY study 58 experienced virologic failure 57 Flu Cy 57 tirofiban 57 nodal metastases 57 oral diclofenac 57 % Confidence Interval 57 confirmed CCyR 57 NNRTI resistance 57 SLNB 57 ALND 57 Secondary endpoints include 57 CI #.#-#.# [001] 57 Partial Responses 57 febrile neutropenia 57 TAXUS Express Stent 57 Univariate analysis 57 partial remissions 57 BRCA2 mutation carriers 57 hematologic toxicity 57 HF hospitalization 57 splenectomized patients 57 heavily pretreated 57 EURIDIS 57 CRp 57 adjuvant radiation 57 clinically meaningful improvements 57 mCRC patients 57 clinically meaningful improvement 57 Primary endpoints 57 REYATAZ r arm 57 ER CHOP 57 plus methotrexate 57 RECIST criteria 57 nonfatal MI 57 completely resected 57 Febrile neutropenia 57 TPV r 57 TLUS 57 gemcitabine cisplatin 57 distant metastasis 57 adalimumab Humira 57 clinicopathological features 57 noninferior 57 intravenous bisphosphonates 57 nondiabetic patients 57 CIMZIA TM certolizumab pegol 57 HBeAg negative patients 57 confidence interval #.#-#.# 57 annualized relapse 57 rebleeding 57 azacitidine 57 virologic failure 57 prednisone prednisolone plus 57 cerebrovascular events 57 placebo PBO 57 mcg kg REBETOL 57 atazanavir ritonavir 57 concurrent chemoradiation 57 cytogenetic response 57 locoregional control 57 adjuvant chemotherapy 57 confidence intervals CIs 57 satraplatin Phase 57 sirolimus eluting stents 57 operable breast cancer 57 adenoma recurrence 57 lung metastases 57 CIMZIA ™ 57 posttransplant 57 HBeAg positive patients 57 DAS# remission 57 R0 resection 57 colorectal adenoma 57 Kaplan Meier estimates 57 salmeterol fluticasone 57 Hazard Ratio 57 Castration Resistant Prostate Cancer 57 Hazard Ratio HR 57 androgen suppression 57 baseline HbA1c 57 liver histology 57 recurrent venous thromboembolism 57 CI #.#-#.# [002] 57 ALT AST 57 intracranial hemorrhage ICH 57 ritonavir boosted 57 β blockers 57 Kaplan Meier method 57 4mg/kg 57 Tumor shrinkage 57 FluCAM arm 57 fosamprenavir 57 neoadjuvant chemotherapy 57 HBeAg 57 CIN3 57 sustained virological response 57 platinum refractory 57 p = .# [002] 57 tumor histology 57 cancer mCRC 57 detectable HCV RNA 56 serum urate 56 imatinib therapy 56 tumor recurrence 56 CANCIDAS 56 p = #.# [003] 56 dacarbazine chemotherapy 56 fluorouracil 56 TAVR 56 FOLFOX6 56 femoral neck BMD 56 revascularizations 56 Median survival 56 advanced adenoma 56 liposomal amphotericin B 56 deep venous thromboses 56 beta blocker therapy 56 lenalidomide dexamethasone 56 tumor regressions 56 unresectable HCC 56 adjunctive placebo 56 advanced adenomas 56 perioperatively 56 HSCT 56 incidence ≥ 56 ribavirin therapy 56 pamidronate 56 locoregional disease 56 neutropaenia 56 adverse cytogenetics 56 multivariate analyzes 56 elacytarabine 56 cytoreduction 56 hsCRP levels 56 #mg BID [001] 56 mcg Albuferon 56 % CI #.#-#.# [008] 56 lamivudine monotherapy 56 placebo p = 56 postoperative mortality 56 irinotecan cisplatin 56 adriamycin 56 EBRT 56 unfractionated heparin 56 recurrent glioblastoma multiforme 56 vincristine doxorubicin 56 nicardipine 56 nonmetastatic 56 pyrexia mucositis sepsis febrile 56 insulin detemir 56 XELOX 56 Response Evaluation Criteria 56 efficacy evaluable 56 symptomatic intracranial 56 FluCAM 56 IFN α 56 dose cohort 56 sustained virologic response 56 cisplatin gemcitabine 56 DLTs 56 curative resection 56 concomitant antibiotics 56 morphometric vertebral fractures 56 specific antigen PSA 56 -#.# log# 56 androgen deprivation 56 standard chemotherapy regimen 56 6MWD 56 preintervention 56 cyclophosphamide methotrexate 56 GP IIb IIIa inhibitors 56 hepatocellular carcinomas 56 iniparib BSI 56 mcg albinterferon alfa 2b 56 TAXUS p value 56 KRAS mutations 56 carboplatin chemotherapy 56 SUVmax 56 preoperative PSA 56 Lucentis monotherapy 56 radical prostatectomy RP 56 Postoperative complications 56 atorvastatin #mg 56 ACR# responses 56 low dose cytarabine 56 multivariate adjustment 56 lymphopenia 56 recurrent GBM patients 56 SNP rs# [002] 56 intravascular hemolysis 56 XIENCE V demonstrated 56 #mg QD [002] 56 platelet reactivity 56 troponin T 56 multivariate Cox 56 localized renal 56 IOP lowering 56 inhospital mortality 56 events MACE 56 relapsed SCLC 56 idraparinux 55 KRAS status 55 desvenlafaxine succinate 55 thrombotic complications 55 HER2 overexpression 55 oral clodronate 55 fibrinolytic therapy 55 KRAS mutations occur 55 neutropenia dehydration dyspnea 55 TAXUS Liberte Long 55 CTEPH 55 #Gy 55 nonresponders 55 advanced neoplasia 55 intact parathyroid hormone 55 reintervention 55 CRu 55 eculizumab therapy 55 QALE 55 #.#/#.# mmHg [001] 55 hepatic metastases 55 odds ratios ORs 55 ALIMTA cisplatin 55 interquartile range 55 irbesartan 55 ventricular dysfunction 55 parkinsonian symptoms 55 titration phase 55 plasma HCV RNA 55 leukocyte count 55 #mg QD [001] 55 secondary efficacy endpoint 55 myocardial necrosis 55 #mg/m# [002] 55 BARACLUDE ® 55 dose cytarabine 55 tapentadol ER 55 cisplatin chemotherapy 55 cEVR 55 dacarbazine 55 Secondary efficacy endpoints 55 genotypic resistance 55 ALT flares 55 STRIDE PD 55 VT VF 55 lymphadenectomy 55 BEXXAR Therapeutic Regimen 55 periprocedural MI 55 rFSH 55 pheochromocytoma 55 anti leukemic 55 galiximab 55 docetaxel chemotherapy 55 metastatic malignant melanoma 55 K ras mutations 55 rosuvastatin #mg 55 statistically significant p = 55 dosage regimens 55 TAXUS VI 55 histologic subtype 55 ovarian carcinoma 55 follicular lymphoma FL 55 infliximab monotherapy 55 seroprotection 55 antiretroviral naive 55 maximal doses 55 tumor resection 55 darunavir r 55 serum creatinine levels 55 stent thromboses 55 achieved sustained virological 55 non squamous NSCLC 55 bolus dose 55 abciximab 55 QTc 55 attain statistical significance 55 pooled comparator 55 receiving INTRON 55 #.#mg/dL 55 nab paclitaxel 55 basal bolus regimen 55 ARCALYST ® 55 KRAS wild 55 FOLFOX regimen 55 prospectively stratified 55 radiotherapy RT 55 TMC# r 55 peripheral sensory neuropathy 55 adjuvant radiotherapy 55 methylprednisolone 55 univariate 55 RECIST Response Evaluation Criteria 55 primary percutaneous coronary 55 coinfected patients 55 serum testosterone 55 breast carcinoma 55 dosing cohorts 55 Bezielle 55 mitoxantrone chemotherapy 55 prior nephrectomy 55 saline placebo 55 CVD mortality 55 methotrexate monotherapy 55 multicenter randomized controlled 55 serum clusterin levels 55 glycosylated hemoglobin levels 55 diagnosed multiple myeloma 55 gemcitabine 55 ATACAND 55 postprocedure 55 interferon ribavirin 55 death reinfarction 55 interferon alfa 55 PREZISTA r 55 mcg BID 55 antiangiogenic therapy 55 virologic failures 55 tiotropium 55 achieved statistical significance 55 bosentan 55 budesonide pMDI 55 contralateral breast cancer 55 distant metastases 55 HBeAg negative 55 hematological parameters 55 BENICAR HCT 55 Percutaneous Coronary Intervention 55 sUA 55 cabazitaxel 55 orchiectomy 55 untreated multiple myeloma 55 eplerenone 55 MAS XR 55 LPV r 55 stage IIIB 55 CC genotype 55 DAPT 55 ICD implants 55 retrospective cohort 55 tumor shrinkage 55 postoperative morbidity 55 inhospital 55 mutated KRAS 55 NSTE ACS 54 nonfatal myocardial infarction 54 pulmonary exacerbation 54 antioxidant supplementation 54 Pharmacokinetics PK 54 acute STEMI 54 small lymphocytic lymphoma 54 FDA defined valvulopathy 54 SCr 54 Kaplan Meier 54 ximelagatran 54 cTnI 54 Zometa hazard 54 hemoglobin A1c levels 54 tenecteplase 54 liver metastasis 54 malignant neoplasms 54 Platinol ® cisplatin 54 radiochemotherapy 54 baseline LDH 54 Platelet counts 54 TroVax ® 54 composite endpoint 54 ADCS ADL 54 malignancy HCM 54 reoperation 54 perioperative morbidity 54 secondary efficacy endpoints 54 noncardiac 54 microg 54 Aptivus ® 54 serum phosphate levels 54 echocardiographic parameters 54 #μg [002] 54 plus MTX 54 NEVO ™ 54 Postoperative 54 adefovir treated 54 #.#ng/ml 54 Femara letrozole 54 unresectable stage 54 TDF FTC 54 iodixanol 54 neoadjuvant therapy 54 endophthalmitis 54 receiving golimumab 54 Pegasys plus Copegus 54 mcg linaclotide 54 hip BMD 54 thromboembolism 54 F FDG PET 54 ischemic lesions 54 symptomatic carotid stenosis 54 prostate cancer CaP 54 GnRH agonist 54 pharmacodynamics PD 54 MMSE score 54 subanalysis 54 non squamous histology 54 mg BID dose 54 â ‰ ¥ 54 etanercept 54 external beam radiotherapy 54 pancreatic adenocarcinoma 54 glycosylated hemoglobin HbA1c 54 HbA 1c 54 refractory acute myeloid 54 unfavorable cytogenetics 54 radical nephrectomy 54 antibody titer 54 docetaxel Taxotere 54 #ug [001] 54 UACR 54 oral FTY# 54 refractory ischemia 54 sinus rhythm 54 receiving highly emetogenic 54 Toxicities 54 PRADAXA #mg 54 symptomatic intracerebral hemorrhage 54 extracapsular extension 54 mesalamine granules 54 mg QD 54 antiandrogen 54 repeat paracentesis 54 log# IU mL 54 HBeAg + 54 rapid virologic response 54 paraprotein 54 APTIVUS R 54 CYP#D# inhibitor 54 CYPHER Stent 54 pemetrexed 54 prednisone prednisolone 54 demonstrated antitumor activity 54 fluvastatin 54 histologically confirmed 54 DOXIL 54 daunorubicin 54 virological response 54 liver resection 54 Pred Forte 54 cilostazol 54 ACEI ARB 54 CHOP chemotherapy 54 relapsed CLL 54 ertapenem 54 CHAMPION PCI 54 venlafaxine XR 54 MAGE A3 ASCI 54 intima media thickness 54 protease inhibitor PI 54 statistically significant improvement 54 pharmacokinetics PK 54 ribavirin RBV 54 metastatic CRC 54 mcg kg 54 transaminase elevations 54 metastatic castration resistant 54 lowest tertile 54 postoperative AF 54 discontinuations due 54 leukopenia 54 fibrinolysis 54 Lupuzor ™ 54 abiraterone acetate 54 divalproex sodium 54 Ishak fibrosis score 54 oral rivaroxaban 54 infliximab therapy 54 FUSILEV enhances 54 androgen blockade 54 severe hypoglycaemia 54 unfractionated heparin UFH 54 variceal hemorrhage 54 generalized edema 54 plasma cortisol 54 WBRT alone 54 aspartate aminotransferase AST 54 decitabine 54 Multivariate analysis 54 piperacillin tazobactam 54 ICD implantation 54 clinically evaluable patients 54 Hb A1C 54 % CI #.#-#.# [006] 54 Subgroup analyzes 54 mg BID 54 ARCOXIA 54 fatigue asthenia 54 unstable angina pectoris 54 metastatic GIST 54 vaginal hysterectomy 54 TACE 54 pretransplant 54 nadroparin 54 ACR# ACR# 54 postoperative radiotherapy 54 metastatic RCC 54 pegylated interferon alfa 54 gout flares 54 Elitek 54 #mg/kg [002] 54 flutamide 54 HOMA IR 54 HbA1C 54 randomized multicenter Phase III 54 calculated creatinine clearance 54 NLX P# 54 nilotinib 54 mL/min/#.# m 2 54 spontaneous preterm delivery 54 relapsed AML 54 steroid dexamethasone 54 bortezomib refractory 54 anthracycline taxane 54 Halaven 54 Kaplan Meier estimate 54 radioiodine therapy 54 calcineurin inhibitor 54 mg p = 54 intravesical therapy 54 corticosteroid dose 54 conjugated equine estrogen 54 mcg dose 54 viral kinetics 54 foveal thickness 54 noninferiority 54 nonvertebral fractures 54 amoxicillin clavulanate 54 Scale cognitive subscale 54 hematologic adverse 54 ibandronate 54 radical cystectomy 54 euthyroid 54 NATRECOR ® 54 logistic regression analysis 54 goserelin 54 laboratory abnormalities 54 taxotere 54 pancreatic resection 54 leukemia AML 54 pneumonectomy 53 alanine aminotransferase 53 serum calcium levels 53 retransplantation 53 idarubicin 53 Kaplan Meier curve 53 nucleoside naive patients 53 adjunctive ABILIFY 53 riociguat 53 ABVD 53 colectomy 53 peginterferon alfa 2b 53 parous women 53 dose Iluvien 53 haematologic 53 nephrectomy 53 thrombocytopenic 53 IIIa inhibitor 53 BPH Symptom Score 53 HbA1c levels 53 anemia hemoglobin 53 AUA Symptom Score 53 erlotinib 53 oral allopurinol 53 BARACLUDE r 53 ACTEMRA TM 53 liver transplant recipients 53 graft patency 53 peginterferon 53 atrioventricular block 53 dapagliflozin plus 53 comparator PI r 53 efavirenz EFV 53 % CI #.#-#.# [005] 53 ADAS cog 53 -#.# log# copies mL 53 tumor regression 53 relapsed refractory multiple myeloma 53 rFVIIa 53 duplex ultrasonography 53 teriflunomide 53 basal cell carcinoma BCC 53 tolterodine ER 53 baseline A1C 53 anthracycline containing 53 HES CEL 53 clinically meaningful differences 53 MitraClip device 53 Taxus Stent 53 pulmonary capillary wedge 53 mCRPC 53 BR.# 53 dose melphalan 53 timepoints 53 bone scintigraphy 53 NIHSS 53 Neoadjuvant 53 OPCAB 53 intraocular inflammation 53 dacarbazine DTIC 53 postoperatively 53 PANSS scores 53 total thyroidectomy 53 noncardiovascular mortality 53 p = #.# [004] 53 CIMZIA TM 53 nonsignificant difference 53 RLAI 53 Torisel 53 complete cytogenetic 53 TAXUS Stent 53 LVSD 53 HGPIN 53 serum ALT 53 baseline CD4 + 53 pharmacodynamic PD 53 postmenopausal osteoporotic women 53 mycophenolate 53 upper gastrointestinal bleeding 53 workhorse lesions 53 deletion 5q 53 TNF blocker therapy 53 stent implantation 53 ADAS Cog 53 sentinel lymph node biopsy 53 differentiated thyroid 53 serum HBV DNA 53 solifenacin 53 ASCT 53 efficacy endpoint 53 aprepitant 53 confidence interval CI 53 CsA 53 clopidogrel pretreatment 53 paclitaxel chemotherapy 53 Teriflunomide 53 multivariable adjusted 53 esophagectomy 53 MCyR 53 nonmetastatic prostate cancer 53 Pemetrexed 53 highly emetogenic 53 subgroup analyzes 53 paroxysmal AF 53 relapsing multiple sclerosis 53 randomized blinded 53 prior chemotherapy regimens 53 hypoglycemic events 53 neutropenic patients 53 Psoriasis Area 53 mg/m2 cohort 53 OGTT 53 intravenous bolus 53 RBC transfusion 53 symptomatic intracranial hemorrhage 53 COPD exacerbations 53 Decitabine 53 Cmax 53 WBRT plus 53 receiving APTIVUS r 53 adalimumab 53 viral kinetic 53 oxymorphone ER 53 mITT population 53 Fludara 53 FOLFIRINOX 53 receiving prophylactic anticoagulation 53 statistical significance p 53 ischemic cardiomyopathy 53 prostate carcinoma 53 aPTT 53 lamivudine refractory patients 53 undergoing coronary artery 53 dasatinib 53 glufosfamide 53 CK # plasma concentrations 53 serum phosphorus 53 = #.#-#.# 53 Stage IIIb 53 salmeterol fluticasone propionate 53 events TEAEs 53 epirubicin cyclophosphamide 53 antibody titers 53 telaprevir dosed 53 clinically localized prostate 53 chemotherapy docetaxel 53 Pharmacokinetic 53 renal cell carcinomas 53 sunitinib 53 UPDRS scores 53 moderately emetogenic 53 IV NSCLC 53 LEXIVA r 53 transplant ASCT 53 invasive aspergillosis 53 trastuzumab 53 imipenem 53 Q2W 53 titrated glipizide 53 mucosal healing 53 symptom exacerbation 53 anastrozole 53 elevated transaminases 53 EDSS score 53 epirubicin 53 surgical debulking 53 HIV RNA 53 paclitaxel cisplatin 53 viral titers 53 DAS# CRP 53 target lesion revascularization 53 hepatic resection 53 underwent percutaneous coronary 53 log# copies mL 53 mean baseline HbA1c 53 femoral neck fracture 53 imetelstat 53 CK MB 53 thrombotic events 53 D dimer 53 ALT normalization 53 sunitinib Sutent 53 endometrial hyperplasia 53 plasma uric acid 53 NPH insulin 53 plus ribavirin 53 LNG IUS 53 macroalbuminuria 53 IPAH 53 ACUITY trial 53 receiving SIMPONI 53 proximal DVT 53 naïve HCV 53 pulmonary artery banding 53 Key secondary endpoints 53 + PH# 53 ± SEM 53 cytoreductive surgery 53 elevated troponin 53 reactogenicity 53 plus COPEGUS 53 p = #.# [002] 53 relapsed refractory 53 pg ml 53 docetaxel 53 glycated hemoglobin levels 53 neutrophil count 53 Kaplan Meier curves 53 tipranavir 53 PREZISTA ritonavir 53 transaminase levels 53 refractory colorectal cancer 53 PegIFN RBV 53 lopinavir r arm 53 events SAEs 53 HERCEPTIN 53 temsirolimus 53 cetuximab 53 HAM D# scores 53 Timed Walk 53 hENT1 53 weekly subcutaneous injections 53 #mg/day [002] 53 peginterferon alfa 2a 53 tigecycline 53 pathologic fractures 53 EGFR tyrosine kinase inhibitors 53 nonoperative treatment 53 serum phosphorous 53 VTE prophylaxis 53 histological subtype 53 transurethral resection 53 suboptimal adherence 53 elective percutaneous coronary 53 graft occlusion 53 DMARD 53 Celsentri Selzentry 53 asymptomatic PAD 53 #mg dose [003] 53 extensive metabolizers 53 Patency 53 TOP2A 53 temozolomide TMZ 52 β blocker 52 degarelix 52 venous blood clots 52 TAXUS V 52 XIENCE V vs. 52 colorectal neoplasia 52 mutated K ras 52 colesevelam HCl 52 sirolimus eluting stent 52 anthracyclines taxanes 52 malignant neoplasm 52 cytogenic 52 interferon alfa 2b 52 lispro 52 CMV disease 52 EGFR TKI 52 mg kg cohorts 52 pyrazinamide